Fundraising Fox

Auron Therapeutics

Newton, US · Founded 2018 · Delaware corporation · 3 known investors

Find your way into Auron Therapeutics

157 people in our graph share verified history with the Auron Therapeutics team — schools, employers, funds. One of them is your warm intro.

David Schenkeinunlockedknows Kate Yen · together at Agios Pharmaceuticals (overlapped)
knows the team · via Agios Pharmaceuticals
×9knows the team · via UCLA
knows the team · via Auron Therapeutics
Biotech

Founders & leadership

Auron Therapeutics was founded in 2018 by Katharine Yen and Kate Yen.

KY
Katharine YenCo-founder
KYKate Yen
Kate YeninFounder, CEOKate Yen holds a Ph.D. in molecular biology from UCLA and conducted post-doctoral research on prostate cancer mechanisms, developing a transgenic mouse model of the disease. She later worked in drug discovery at Merck Research Laboratories and Agios Pharmaceuticals, focusing on oncology target identification and validation.
CG
Christopher GuiffreExecutive

Board

AL
Alon LazarusBoard director
AFAnna French
Anna FrenchinBoard DirectorDirector at Renasant Bio
ACAlexandra Cantley
Alexandra Cantleyin𝕏Board MemberManaging Partner at Polaris Partners
ESEric Shiozaki
Eric ShiozakiinBoard directorPartner at Revelation Partners
PO
Pini OrbachBoard director
SMSerge Messerlian
Serge MesserlianinMember Board of DirectorsOperating Partner, DCVC Bio at DCVC Bio
VR
Victoria RichonBoard director
BD
Briggs Duncan MorrisonBoard director

Investors · 3

DCVC (Data Collective)Palo Alto · $5M – $25M
DCVC BioreportedPalo Alto
Polaris Partnersreported · 2 sourcesBoston · $500K – $5Mvia Alexandra Cantley · board

Reported raises · per SEC filings

Form D private placements

$88.9M disclosed across 5 rounds · 2018–2026

▶$7.1MraisedAug 2026 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Katharine YenExecutive Officer, Director
  • Alexandra CantleyDirector
  • Briggs Duncan MorrisonDirector
  • Anna FrenchDirector
  • Pini OrbachDirector
  • Serge MesserlianDirector
  • Victoria RichonDirector
Offering amount
$12M
Amount sold
$7.1M
First sale
Aug 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$27.3MraisedDec 2025 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Briggs Duncan MorrisonDirector
  • Pini OrbachDirector
  • Katharine YenExecutive Officer, Director
  • Alexandra CantleyDirector
  • Victoria RichonDirector
  • Anna FrenchDirector
  • Serge MesserlianDirector
Offering amount
$42.3M
Amount sold
$27.3M
First sale
Dec 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$38.4MraisedOct 2023 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Christopher GuiffreExecutive Officer
  • Alon LazarusDirector
  • Anna FrenchDirector
  • Katharine YenExecutive Officer, Director
  • Victoria RichonDirector
  • Briggs Duncan MorrisonDirector
  • Alexandra CantleyDirector
  • Eric ShiozakiDirector
Offering amount
$48.2M
Amount sold
$38.4M
First sale
Jul 2022
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.4MraisedDec 2020 · 25 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Isaac CiechanoverDirector
  • Katharine YenExecutive Officer, Director
  • John Duncan HiggonsDirector
  • Alon LazarusDirector
  • Anna FrenchDirector
Offering amount
$15.4M
Amount sold
$15.4M
First sale
Dec 2020
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$660KraisedJul 2018 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Katharine YenExecutive Officer, Director
  • John Duncan HiggonsDirector
Offering amount
$1.5M
Amount sold
$660K
First sale
Jun 2018
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Auron Therapeutics went on to found or lead other companies.

Serge MesserlianMember Board of DirectorsFounded Creyon +1Rami HannoushBoard ObserverFounded Epi Biologics

In the news

Auron Therapeutics raises Series B to test cancer drug in the clinic - Bizwomenbizjournals.com · Feb 2025Auron Therapeutics Announces FDA Clearance and Series B Financingclinicaltrialvanguard.com · Feb 2025Medpathtrial.medpath.com · Feb 2025Auron Therapeutics Announces FDA Clearance to Initiate Clinical Development of AUTX-703 and Completion of Series B Financingglobenewswire.com · Feb 2025Auron Therapeutics Raises $48M in Series A Financingfinsmes.com · Jul 2022With hopes of paving new path for cancer treatment, Eli Lilly-backed Auron raises $48Mfiercebiotech.com · Jul 2022

Frequently asked questions

Who founded Auron Therapeutics?
Auron Therapeutics was founded by Katharine Yen, Kate Yen in 2018.
Who are Auron Therapeutics's investors?
Auron Therapeutics's investors include DCVC (Data Collective), DCVC Bio, Polaris Partners.
How much funding has Auron Therapeutics raised?
Auron Therapeutics has disclosed $88.9M raised across 5 rounds.
Where is Auron Therapeutics headquartered?
Auron Therapeutics is headquartered in Newton, US.